Q2 2026 saw 13% revenue growth, margin expansion, and record new patient starts across U.S. and international markets. Strong CONNECT trial results and expanded coverage support future growth, while guidance was raised for revenue and margins.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.